New PET scan tracer could spot hidden blood cancers
NCT ID NCT06636175
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new radioactive imaging agent called 64Cu-LLP2A to see if it can safely and clearly show blood cancers like multiple myeloma and lymphoma on PET/CT scans. The study includes healthy volunteers and patients with these cancers, including those who have had a bone marrow transplant and may have a recurrence. The main goals are to confirm the agent's safety and measure the radiation dose to organs, as well as to evaluate the quality of the images it produces.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 64Cu-LLP2A (a radioactive imaging agent)
- What this could lead to
- If successful, this could lead to a more accurate PET/CT scan for detecting and monitoring certain blood cancers, helping doctors find hidden disease.
- What could go wrong
- This is a very early (phase 1) study with only 42 participants, so it is mainly checking safety and image quality, not yet proving it works better than current scans. The imaging agent is experimental and may not improve detection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas